BCRX (BioCryst Pharmaceuticals) Tariff Resilience Score: 4/10 (As of Jul. 02, 2026)


BCRX BioCryst Pharmaceuticals Inc BCRX
66 GF Score
Price $9.65
GF Value $12.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Tariff Resilience Score?

BioCryst Pharmaceuticals BCRX -3.40% 66 Tariff Resilience Score is 4 as of Jul. 02, 2026. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,029 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks better than 79.88% on this metric.

BioCryst Pharmaceuticals has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

BioCryst Pharmaceuticals has BioCryst relies on global supply chains for pharmaceutical ingredients, making it vulnerable to tariffs. The biotech industry has limited tariff exemptions, and past tariffs have affected costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes BioCryst Pharmaceuticals might have Average Resilient.

BioCryst Pharmaceuticals  (NAS:BCRX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

BioCryst Pharmaceuticals Tariff Resilience Score Related Terms

BCRX vs SUPN, PBH, AMLX: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Tariff Resilience Score falls into.


BCRX
66GF Score
BioCryst Pharmaceuticals Inc BCRX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 4 mean?
BioCryst Pharmaceuticals (BCRX) has a Tariff Resilience Score of 4 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #207 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is BioCryst Pharmaceuticals' Tariff Resilience Score too high?
BioCryst Pharmaceuticals' current Tariff Resilience Score is 4. Based on the distribution chart, BioCryst Pharmaceuticals ranks #207 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Tariff Resilience Score compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #207 out of 1029 companies for Tariff Resilience Score. This places BioCryst Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. BioCryst Pharmaceuticals's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.67, compared to a current price of $9.65 — trading 23.8% below its estimated fair value. The current Tariff Resilience Score is 4. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Tariff Resilience Score is 4 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.65 is trading 23.8% below its estimated GF Value™ of $12.67. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Tariff Resilience Score: 4
  • GF Value™: $12.67 vs. price of $9.65 (23.8% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score

Get the complete analysis for BCRX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.65
Price
$12.67
GF Value